Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'.

Predictive markers in breast cancer--the present.

Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer.

Improved breast cancer prognosis through the combination of clinical and genetic markers.

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.

The prognostic impact of some cell cycle regulatory proteins in Egyptian breast cancer patients.

[Integration of new and future biomarkers in the treatment of breast cancer]

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.

Tumor markers for breast cancer.

[Prognostic and predictive factors in breast cancer]

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

Human tetranectin: methodological and clinical studies.

Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.

New generation of molecular prognostic and predictive tests for breast cancer.

The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

HER2--a discussion of testing approaches in the USA.

Molecular prognostic factors for breast cancer metastasis and survival.